Weight-Loss Drugs Change How People Drink in British Pubs

The way people enjoy a night out at the pub is changing, and the reason may be found in medicine cabinets rather than at the bar. Following recent reports about the rise of weight-loss drugs, new information shows that these medications are starting to affect the British hospitality industry. Heineken, one of the world’s largest brewers, has warned pub owners that the growing popularity of GLP-1 drugs—a type of medicine that helps people lose weight by changing how their brain feels about food and appetite—could lead to a noticeable drop in beer and cider sales.

In a presentation shared with British hospitality customers, Heineken explained that the use of drugs like Ozempic and Wegovy is changing consumer behavior. The company noted that these medications can make people feel full faster, which often leads to a lower desire to drink alcohol. As a result, the long-standing British tradition of staying at a pub for several hours to drink multiple pints may become less common. According to The Guardian Business, Heineken believes that this "GLP-1 era" requires pubs to change how they serve customers to stay profitable.

To adapt to these changes, Heineken has suggested that pubs should start promoting different options. This includes offering half-pint servings, increasing the number of low-alcohol or zero-alcohol drinks on the menu, and pairing drinks with small plates of food. The company argues that if pubs do not adjust to these new habits, they risk seeing a decline in both the number of visitors and the total amount of money spent at their businesses. A spokesperson for Heineken stated that they are carefully monitoring how these behaviors evolve throughout 2027, noting that consumer habits are changing in response to many different trends, not just health medication.

This trend is backed by data from various research firms. According to The Guardian Business, research companies such as Circana, NIQ, and KAM have all conducted surveys showing that people using GLP-1 drugs are drinking less alcohol. This is a significant concern for the industry, as beer sales in British pubs, bars, and restaurants reached almost £14bn in the year leading up to February. Currently, only a very small portion of that total comes from low- or no-alcohol products, leaving plenty of room for these new, healthier options to grow.

However, not every company in the industry shares the same level of worry. While Heineken is preparing for a shift in the market, other major players have different views. The Guinness maker, Diageo, has told its investors that it expects any impact from these drugs to be manageable. Meanwhile, the brewer Carlsberg has taken a more skeptical approach, telling reporters that current data does not support the idea that weight-loss drugs are causing a major change in beer consumption trends.

Heineken’s spokesperson emphasized that the situation is complex. They noted that people using these drugs are not simply giving up alcohol entirely. Instead, they are becoming more "purposeful" in their choices, which means they are being more careful about what and how much they consume. This behavior is part of a broader shift toward health and wellbeing that is being seen across many different markets. Consumers today are looking for more choice and more intentional consumption, whether they are using weight-loss medication or simply trying to live a healthier lifestyle.

As the popularity of these drugs continues to grow—with research by JP Morgan showing that 10 million people in the United States turned to such medication last year—the hospitality industry will likely continue to face pressure to innovate. Whether this leads to a permanent change in the culture of the British pub remains to be seen. For now, brewers and pub owners are watching the data closely, trying to find the right balance between maintaining their traditional business models and meeting the changing needs of a health-conscious public.